SLOUGH, U.K., Oct. 28, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announced the achievement of a milestone in its agreement with Amgen Inc. for the research, development and global commercialisation of novel treatments for osteoporosis using Celltech's proprietary antibody fragment technology, which aims to identify antibody fragments against sclerostin, a protein discovered by Celltech. Sclerostin is involved in the regulation of bone deposition, and it is believed that by inhibiting this protein, bone loss in osteoporosis patients may be reversed. Amgen and Celltech scientists have identified a high-affinity function modifying Celltech antibody for further study, triggering an undisclosed milestone payment to Celltech.
Dr Melanie Lee, Research and Development Director for Celltech, commented: "We are pleased that this innovative programme continues to progress well and with the ability of our SLAM technology to generate high quality, functionally active antibodies against challenging protein targets."
Celltech Group plc (LSE: CCH; NYSE: CLL) is one of Europe's largest biotechnology companies, with an innovative development pipeline funded by its profitable, cash-generative pharmaceutical business. Celltech also possesses drug discovery capabilities of exceptional strength, including a leading position in antibody engineering. More details can be found at www.celltechgroup.com
Notes for Editors
Osteoporosis
Osteoporosis is a degenerative bone disease estimated to affect one-third of women aged 60 to 70, and two-thirds of women aged 80 or older. Current treatments primarily halt loss of bone density, but do not reverse the effects of osteoporosis.
Amgen agreement
Key terms of Celltech's agreement with Amgen, announced in May 2002, are as follows:
- Amgen has exclusive worldwide rights to develop and market treatments targeting the Sclerostin protein. - Celltech is responsible for the identification and engineering of high affinity PEGylated antibody fragments against the Sclerostin protein, using its SLAM technology and proprietary antibody fragment technology. - Celltech will pay a proportion of all early development costs. - Amgen will be responsible for worldwide development. - Celltech has the option to co-invest in late stage development and may then lead promotional activities in the European Union. Amgen will lead promotion in North America and Japan. - Alternatively, if Celltech chooses not to participate in development, Amgen will become the exclusive licensee for this program and will continue to develop and market products against the Sclerostin protein on a worldwide basis. Celltech would then receive royalties based on sales achieved by Amgen.
Celltech desires to take advantage of the 'Safe Harbor' provisions of the US Private Securities Litigation Reform Act of 1995, with respect to forward-looking statements contained within this document. In particular certain statements with regard to expectations about the therapeutic potential of antibody-based products targeting sclerostin are forward-looking in nature. By their nature forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. In addition to factors set forth elsewhere in this document, the following factors, although not exhaustive, could cause actual results to differ materially from those the Company expects: the risk that the effects of products arising from this collaboration in humans may not be as expected or may not be consistent with the scientific rationale or that there may be safety issues, unexpected technical or manufacturing hurdles and intellectual property disputes, and the failure of the Company's development, manufacturing and marketing partners to perform their contractual obligations. Other factors that could affect these forward-looking statements are described in the Company's reports filed with the US Securities and Exchange Commission. The forward-looking statements included in this document represent the Company's best judgment as of the date hereof based in part on preliminary information and certain assumptions which management believes to be reasonable. The Company disclaims any obligation to update these forward-looking statements.
This information is provided by RNS
The company news service from the London Stock Exchange